Please use this identifier to cite or link to this item: https://www.um.edu.mt/library/oar/handle/123456789/1029
Full metadata record
DC FieldValueLanguage
dc.contributor.authorZarb, Peter-
dc.contributor.authorBorg, Michael Angelo-
dc.date.accessioned2015-01-28T12:10:46Z-
dc.date.available2015-01-28T12:10:46Z-
dc.date.issued2011-
dc.identifier.citationMalta Medical Journal. 2011, Vol.23(2), p. 13-18en_GB
dc.identifier.urihttps://www.um.edu.mt/library/oar//handle/123456789/1029-
dc.description.abstractBackground: Antibiotic use is recognised as the most important driver for the development of antimicrobial resistance in community pathogens. Surveillance is therefore critical for improvement programmes. Methods: Antimicrobial distribution data for the years 2007 to 2009 were collected retrospectively by the National Antibiotic Committee from all licensed wholesale distributors (WSL) in Malta and analysed according the World Health Organization Anatomical Therapeutic Chemical classification (ATC) level 4 criteria. Results: Overall consumption increased from 18.6 defined-daily-doses/1000-inhabitant-days (DID) in 2007 to 22.7 DID in 2008 and reached 24.4 DID in 2009 - an increase of more than 30% over the three years, Penicillins with beta-lactamase inhibitor increased in volume (7.1 to 8.8 DID) but decreased in proportion (38.4% to 36.0%) between 2007 and 2009. On the other hand, second generation cephalosporins increased in both volume and proportion (2.8 to 5.4 DID; 15.0% to 22.0%). The proportion for macrolides remained stable at approximately 16% but the volume of use again increased (2.9 DID to 3.9 DID). Fluoroquinolone proportion decreased from 9.1% to 6.8%, maintaining a stable volume of use in the region of 1.7 DID. Conclusions: Antibiotic consumption in Malta has shown a consistent increasing trend over the past three years, despite a reduction in over-the-counter acquisition. Furthermore, there is evidence of a strong, and possibly unjustified, prescription of wide spectrum antibacterials. This is potentially an important driver for documented resistance in Streptococcus pneumoniae and Escherichia coli and needs to be addressed at a national level.en_GB
dc.language.isoenen_GB
dc.publisherMalta Medical Journalen_GB
dc.rightsinfo:eu-repo/semantics/openAccessen_GB
dc.subjectAntibiotics -- Drug utilization -- Maltaen_GB
dc.subjectAntibiotics -- Drug utilization -- Monitoringen_GB
dc.subjectAmbulatory medical care -- Maltaen_GB
dc.titleConsumption of antibiotics within ambulatory care in Maltaen_GB
dc.typearticleen_GB
dc.rights.holderThe copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holder.en_GB
dc.description.reviewedpeer-reviewed-
Appears in Collections:MMJ, Volume 23, Issue 2
MMJ, Volume 23, Issue 2
Scholarly Works - FacM&SCPT
Scholarly Works - FacM&SPat

Files in This Item:
File Description SizeFormat 
2011.Vol23.Issue2.A3.pdfConsumption of antibiotics within ambulatory care in Malta224.89 kBAdobe PDFView/Open


Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.